What is the specific market price of Alpelisib?

Alpelisib (Alpelisib)-Piqray is a targeted drug for PIK3CA mutant breast cancer , developed by Novartis Pharmaceuticals, with the trade name Piqray. According to the approval of the FDA and EMA, Apelvis is suitable for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer, and is usually used in combination with Fulvestrant. Such patients often develop drug resistance or disease progression after receiving endocrine therapy such as aromatase inhibitors, and apelvis brings new treatment possibilities to such patients by targeting the inhibition of the PI3Kα pathway.

PIK3CA mutation is one of the common genetic abnormalities in breast cancer. Mutations result in sustained activation of PI3K signaling, which promotes cancer cell growth and survival. The clinical application of Apelvis is positioned on this molecular mechanism. By targeting the mutated PI3Kα protein, it effectively reverses hormone resistance and provides a new option for patients to extend their progression-free survival. The drug has shown good safety and controllability in clinical applications. The main adverse reactions include hyperglycemia, rash, fatigue, nausea and diarrhea, etc. Most of them can be alleviated through dose adjustment or supportive treatment.

The original drug of Apelvis has not yet been officially launched in mainland China, and there is no official data on the domestic selling price. In overseas markets, especially in Europe and India, there are obvious differences in the price of Apelis. The price of each box of the European version of Apelvis (150mg × 56 tablets) may exceed RMB 40,000, while the price of the Indian version of the original drug (150mg × 28 tablets) is about more than RMB 5,000. The price gap is mainly due to differences in regional pricing policies and channels. At the same time, generic versions of drugs have appeared in some Asian regions. For example, the generic version of Apelvis produced in Laos and other places costs about RMB 2,000 per box (150 mg × 28 tablets). The specific selling price may be affected by exchange rate and channel fluctuations.

Reference materials:https://www.piqray.com/